Vista modulators for diagnosis and treatment of cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 13, 2018
Issued Date -
N/A
app pub date -
Jan 17, 2014
filing date -
Jun 22, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).
First Claim
Other Claims data not available
Family
International Classification(s)
- 2014 Application Filing Year
- A61K Class
- 14144 Applications Filed
- 11600 Patents Issued To-Date
- 82.02 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 21 Citation Count
- A61K Class
- 98.50 % this patent is cited more than
- 7 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Aug 13, 2025 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Aug 13, 2029 |
